Beam Therapeutics BEAM Debt-to-equity

Debt-to-equity at other companies

Vertex PharmaceuticalsVRTX

0.1×0.0×

Arrowhead ResearchARWR

0.2×0.0×

Ultragenyx PharmaceuticalRARE

3.7×—

MGN

MagniteMGNI

0.5×-0.6×

Wave Life SciencesWVE

0.1×-0.1×

Intellia TherapeuticsNTLA

0.1×—

FAQ

What is Beam Therapeutics's debt-to-equity?

Beam Therapeutics (BEAM) reported debt-to-equity of 0.2× in Q1 2026.

How has Beam Therapeutics's debt-to-equity changed year-over-year?

Beam Therapeutics's debt-to-equity increased by 53.9% year-over-year, from 0.1× to 0.2×.

What is the long-term trend for Beam Therapeutics's debt-to-equity?

Over 5 years (2020 to 2025), Beam Therapeutics's debt-to-equity has grown at a -22.3% compound annual growth rate (CAGR), from 0.4× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.